Here are the 10-K annual reports from Ocugen, Inc. (OCGN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow OCGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OCGN filings page.
Ocugen, Inc. is a late-stage biotechnology company focused on gene therapies and biologics for serious eye diseases, a regenerative knee cartilage implant, and an inhaled mucosal vaccine platform. Its lead modifier gene therapy, OCU400 for retinitis pigmentosa, has completed Phase 3 enrollment of 140 subjects, with a rolling BLA planned to begin in the third quarter of 2026 and topline data expected in the first quarter of 2027. Long-term Phase 1/2 data show approximately 2-line LLVA gains and durable safety across multiple mutations.
OCU410 and OCU410ST, both based on the RORA gene, target geographic atrophy and Stargardt disease, respectively. Phase 2 ArMaDa data for OCU410 showed a 46% reduction in lesion growth at 12 months versus control and a favorable safety profile, while Phase 1 GARDian1 data for OCU410ST showed atrophic lesion growth 54% slower at 12 months in treated eyes and 100% stabilization or improvement in visual function among evaluable treated eyes. A 51-patient Phase 2/3 pivotal trial for OCU410ST is underway, with enrollment expected to complete in early 2026 and a BLA submission planned in the first half of 2027.
The company is also developing OCU200, a fusion protein for DME, DR, and wet AMD now in a multicenter Phase 1 trial, and NeoCart, a Phase 3-ready autologous knee cartilage implant held in its OrthoCellix subsidiary. Its inhaled COVID-19 vaccine candidate OCU500 will enter a Phase 1 trial funded by NIAID’s Project NextGen, and Ocugen reports 80 patents and 66 pending applications worldwide supporting its pipeline and partnered programs.